New scan may help match breast cancer patients to the right drug
NCT ID NCT07471776
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a new type of PET scan (TROP2-PET) can predict how well certain targeted drugs work in people with advanced HER2-negative breast cancer. The drugs, called antibody-drug conjugates, deliver chemotherapy directly to cancer cells. The study will enroll 45 participants and compare the TROP2-PET scan with a standard FDG-PET scan to see which better predicts treatment response. If successful, this approach could help doctors choose the most effective treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab Govitecan, Datopotamab deruxtecan, Sacituzumab tirumotecan (targeted cancer drugs)
- What this could lead to
- If successful, this imaging method could help doctors predict which patients will benefit from TROP2-targeted drugs, avoiding ineffective treatments.
- What could go wrong
- This is a small, early-phase study (45 participants) focused on imaging accuracy, not treatment outcomes. The prediction model may not be reliable enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.